Inflation Data Climbs Less Than Expected, Giving Stocks A Bump

 | Sep 14, 2021 11:13AM ET

Inflation continues to be a major issue, but today’s August consumer price index (CPI) report offered a flash of hope for anyone who wants to see prices start coming down a bit.

Year-over-year, CPI growth came in at 5.3%, just below analysts’ consensus of 5.4%, so that was something the bulls might be able to hang their hat on. And the monthly growth of 0.3% was just short of the 0.4% Wall Street consensus collected ahead of the report by research firm Briefing.com.

It’s arguably the first glimmer in a while of inflation maybe beginning to cool off slightly after months of huge gains as the economy came out of the COVID lockdown period and supply chains got pressured. There’s still all kinds of supply chain holdups, with the media reporting about ships backed up at ports and rail cars being hard to find. Today’s CPI report showing a slight miss in the inflation numbers doesn’t change any of that, because one report isn’t a trend.

The Fed is likely giving today’s data and last Friday’s producer price index (PPI) a pretty close look as it decides whether it needs to step in and begin ramping down its bond purchase program. A number like today’s, even if it’s lower than expected, indicates that inflation remains a major issue.

h2 Despite Bump From CPI News, Market Remains In “No Man’s Land”/h2

Still, stock index futures appeared to get a nice bump immediately after the data flash. That contrasts with the way stocks came down to finish well off their highs on Monday. A weak close like that sometimes can roll into trading the following session, so keep an eye out for any sort of follow-through to the downside early on.

Also, one day of recovery after a long stretch of weakness doesn’t necessarily mean we’re out of the woods. We’re going into this strange period, where you kind of have a lack of numbers, without much key data after CPI and retail sales this week. Earnings are kind of a desert, too. In this “no man’s land,” the market is looking for anything to trade off.

One thing to consider watching comes later today when Apple (NASDAQ:AAPL) is scheduled to hold an event starting early this afternoon East Coast time. Media reports suggest the event could include the launch of the iPhone 13 and a new Apple Watch. Stay tuned. And remember that in the past, these events haven’t typically lit a huge fire under AAPL shares, but there’s always a first time for everything, as the saying goes.

Yesterday was kind of a “yo-yo” day for the market, in part because people didn’t have a lot of fresh data or earnings to trade on. It could be a “yo-yo” day again today because we’re in this odd period. Meanwhile, the Cboe Volatility Index (VIX) is flirting with 20 again, crude is above $70 a barrel, the 10-year yield is trying to get back to 1.35% and the 30-year yield is trying to get back to 2%.

h2 New Boss Same As Old/h2
Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

The results Monday were a little different after five days of overall market declines, but some of the same factors from last week continued.

Most obviously, the weakness in tech that we’ve seen recently didn’t retreat that much just because the S&P 500 Index and the Dow Jones Industrial Average finished higher yesterday. Instead, three of the five “FAANG” stocks lost ground. Semiconductors gained overall, but two of the most closely followed ones—Nvidia (NASDAQ:NVDA) and Advanced Micro Devices (NASDAQ:AMD)—both finished Monday in the red.

The takeaway here might be that tech stocks have come a long way very fast and there may be some rebalancing going on around the market. Last week’s bad news for AAPL and Alphabet (NASDAQ:GOOGL)—when a judge ruled Apple won’t be allowed to prohibit developers from providing links that direct users away from Apple in-app purchasing— may still be weighing on the sector a bit.

Tech’s tough week continued when shares of Oracle (NYSE:ORCL) fell in trading before Tuesday’s opening bell despite the company’s earnings beating Wall Street’s average expectations. The problem for investors appeared to be ORCL’s revenue, which came up a bit shy of the consensus analyst estimate. Otherwise, it looked like a strong quarter, with ORCL above guidance on most measures. But when you’re going well, the expectations can be so high. Maybe it’s one of those things where people initially sell the news and then take a harder look and reconsider.

h2 Banks, Energy Lead The Pack Early In Week/h2

Enough about tech and its problems, because the energy and financial sectors started the week on a positive note. That showed up very clearly when you consider that the Dow had the best weekly start of any major index, rising more than 0.75%. That index is loaded with banks and energy firms. Energy got a boost Monday in part from—what else—rising crude. But many of the alternative energy stocks rose too, helped in part by news that the Democrats’ proposed $3.5-trillion reconciliation bill would encourage more use of electric vehicles and non-carbon burning energy sources.

For instance, First Solar (NASDAQ:FSLR) rose nearly 7% yesterday and SunPower (NASDAQ:SPWR) rose more than 4%. Tesla (NASDAQ:TSLA) rose nearly 1% and General Motors (NYSE:GM) and Ford (NYSE:F) didn’t get left out either.

It’s a bit early to start counting on anything the bill might do for alternative energy and electric vehicles, because there’s a long way to go to get it passed and various elements might change. Proposed higher tax credits for people who buy electric vehicles manufactured in the U.S. by union labor could be an interesting one to watch, because it seems aimed at helping the GMs and Fs of the world, where union labor is still pretty strong. TSLA doesn’t have a labor union at the plant where it produces its cars for the U.S. market.

Maybe you noticed that the week didn’t get off to as good a start for COVID vaccine makers Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE). The softness might reflect a report in a well-known medical journal casting doubt on the need for booster shots.